A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ.

CONCLUSIONS: CAS predicted 10-year LR risk for patients who underwent surgical management alone and identified patients who may be at low risk of recurrence, and for whom adjuvant RT may not be required. CAS demonstrated the highest concordance among the known prognostic models such as VNPI and clinicopathological variables such as grade, age, and comedo necrosis. PMID: 31937618 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31937618?dopt=Abstract

Source: Clinical Cancer Research - January 13, 2020 Category: Cancer & Oncology Authors: Mittal K, Toss MS, Wei G, Kaur J, Choi DH, Melton BD, Osan RM, Milligy IM, Green AR, Janssen EAM, Søiland H, Gogineni K, Manne U, Rida P, Rakha EA, Aneja R Tags: Clin Cancer Res Source Type: research